Reguliert
Vorzeitig verkaufbar
- Risikostufe
- Sehr hoch
- Risiko-Rendite
- Mittel
- Start ab
- €500
Finanzierung am 20 Sep 2026 abgeschlossen. Die Seite bleibt zur Information online; ähnliche offene Projekte finden Sie unten.
Kairos Discovery
Frankreich
A Lyon-based biotech developing KDX-350, an oral bivalent CK2 inhibitor for colorectal and clear-cell renal cancer, to license to a pharmaceutical partner from 2027.
Eckdaten
- Geschätzte Rendite
- bis zu 20×
- Schätzung der Plattform
- Unternehmensbewertung
- €3,294,118
- Angebotener Anteil
- 21
- Erwarteter Exit
- 2030
- Finanzierung endet
- 20 Sep 2026
- Start ab
- €1,000
- Zielbetrag
- €850,000
Was Ihnen gehört, wie es sich auszahlen kann, und wann
Was gehört mir?
21 des Unternehmens
Prüfen Sie in den Dokumenten, wie die Anteile gehalten werden und welche Rechte sie gewähren.
Wie kann es sich auszahlen?
Die Plattform schätzt bis zu 20×
In der Regel nur, wenn das Unternehmen verkauft wird oder an die Börse geht. Schätzungen sind eigene Angaben der Plattform.
Wann könnte ich Geld erhalten?
Etwa 2030
Nur wenn es zu einem Verkauf oder Börsengang kommt; vorher sind Anteile schwer verkäuflich.
Kapitalverlustrisiko. Die meisten Startups scheitern; Schätzungen sind eigene Angaben der Plattform. Anteile sind vor einem Exit schwer zu verkaufen.
Würde die KI investieren?
KI 63 MittelUnsere KI gibt diesem Projekt 63 von 100 Punkten: Mittel. So funktioniert der KI-Score
Informationen, keine persönliche Anlageberatung. Der KI-Score bewertet die von der Plattform veröffentlichten Dokumente, kann falsch sein und sagt keine Renditen voraus.
KI-Analyse
KIKairos Discovery — Crowdfunding Investor Memo
A French laboratory company designing an experimental cancer medicine that it plans to sell or license to a large pharmaceutical company rather than sell to patients itself.
Sector: Biotechnology (preclinical oncology) · Stage: Seed (preclinical) · HQ: Lyon, France · Raise: €850,000 target (maximum €1,500,000)
Snapshot
|
1 · Is the price fair? 💶 |
5 / 5 — Supported. At €2.8M–€3.3M before this round, the price is below every European early-stage benchmark we located: a median of €5.0M in Q3 2025 and €3.6M over the longer term (PitchBook-derived data, November 2025), a typical seed range of €4M–€12M (Startkeel, 2026), and a European early-stage median of $6.54M for 2020–2025 (Equidam, Q3 2025). |
|
2 · Can they reach an exit stage? ⭐ |
AI SCORE 63 / 100 — Average The strongest evidence is the people and the science: the chairman led a comparable Lyon company to an acquisition by Eli Lilly in 2023, and the underlying research is published in a peer-reviewed chemistry journal with a crystal structure deposited in a public database. The biggest gap is that the medicine being offered here, KDX-350, is not the compound described in that publication, and no data on KDX-350 itself is in the pack we reviewed. |
|
3 · If they do, what could it pay? 🎯 |
Target 20x over 3.5–4.5 years (the company's own plan; the standard expectation for a seed-stage company is about 10x over 5–7 years). If reached, illustratively 5x–50x before fees and before future dilution. Method: the required sale value divided by the €4.09M value of the whole company at this round's price. The low end is a licensing deal at the median upfront payment for a preclinical cancer drug, $22M (Ambrosia Ventures deal database, 2026); the high end is the company's own stated target of more than €200M once the medicine has shown early results in patients. |
How to read the score
|
85–100 · Excellent |
All key preconditions for reaching an exit stage are evidenced and strong — rare at this stage |
|
70–84 · Good |
Preconditions largely in place, with specific gaps — named in the questions section |
|
50–69 · Average |
Meaningful preconditions missing or weakly evidenced |
|
30–49 · Weak |
Several core preconditions absent, or the evidence points against them |
|
1–29 · Critical |
Fundamental preconditions are not visible in the evidence |
|
What we could check. We checked 33 of the company's claims against public sources. The company registration, its 2023 fundraise, the chairman's previous sale of a business to Eli Lilly, the patent family, the peer-reviewed publication and the French tax ruling all check out against public records. The figures for the medicine itself (KDX-350), the letter of interest from a pharmaceutical company, the current cash position and most of the market-size numbers rest on the company's own materials — see the questions section. Your money is locked in. Crowdfunding shares normally cannot be sold early — expect your money to be tied up for several years, until the company is sold or a similar event happens. |
Three answers, one honest note. The fairness score says whether the entry price is supported by the sector benchmarks we could find. The AI Score is our read on whether the company has the building blocks in place to reach a point where a sale or licensing deal can happen — it audits readiness on the evidence disclosed. It is not a measure of how likely success is, and even companies with every building block in place fail more often than they succeed, which is why this kind of investing only works as a small part of a spread-out portfolio. The returns range is an illustration built from named industry benchmarks, not a forecast. Where something was not in the pack we reviewed, it did not lower any score — it appears in the questions list instead, so you can ask the company directly before you invest. The listing was reviewed by a licensed crowdfunding platform before it went live. Nothing here is a recommendation.
At a glance
|
✅ Three reasons to look closer |
⚠️ Three reasons for caution |
|
|
|
Deal terms. No terms were identified in the reviewed documents that would prevent a crowdfund investor from sharing in the upside. Full mechanics are at the end of this memo. One point to check: the two platform documents disagree on a single right. The official Key Investment Information Sheet states there is no prio… |
Die vollständige Analyse behandelt den Kreditnehmer bzw. das Unternehmen, die Sicherheit, den Cashflow, die Risiken und ein Fazit. Melden Sie sich an, um sie zu lesen.
Informationen, keine persönliche Anlageberatung. Der KI-Score bewertet die von der Plattform veröffentlichten Dokumente, kann falsch sein und sagt keine Renditen voraus.
KI zu diesem Projekt fragen
Melden Sie sich an, um der KI Fragen zu den Dokumenten dieses Projekts zu stellen.
AnmeldenGefällt Ihnen dieses Projekt?
👍 Ja · 0 👎 Nein · 0
Kommentare · 0
- Noch keine Kommentare.
Die Plattform und ähnliche Projekte
Angeboten auf
Ähnliche offene Projekte
Kepplair Evolution
Sowefund
- Geschätzte Rendite
- bis zu 7×
- Schätzung der Plattform
- Unternehmensbewertung
- €60,000,000
Ziel: €9m
Ab €500
Projekt ansehen
Wind Fisher
Sowefund
- Geschätzte Rendite
- bis zu 10×
- Schätzung der Plattform
- Unternehmensbewertung
- €9,961,800
Ziel: €600k
Ab €1,000
Projekt ansehen
Blumana
Sowefund
- Geschätzte Rendite
- bis zu 28×
- Schätzung der Plattform
- Unternehmensbewertung
- €2,799,571
Ziel: €750k
Ab €1,000
Projekt ansehen